CureVac

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) You can help expand this article with text translated from the corresponding article in Dutch. (July 2022) Click [show] for important translation instructions. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Dutch Wikipedia article at [[:nl:Exact name of the Dutch article]]; see its history for attribution. You may also add the template {{Translated page|nl|Exact name of Dutch article}} to the talk page. For more guidance, see Wikipedia:Translation. You can help expand this article with text translated from the corresponding article in German. (March 2020) Click [show] for important translation instructions. View a machine-translated version of the German article. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Consider adding a topic to this template: there are already 1,859 articles in the main category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing German Wikipedia article at [[:de:CureVac]]; see its history for attribution. You may also add the template {{Translated|de|CureVac}} to the talk page. For more guidance, see Wikipedia:Translation. This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (July 2022) (Learn how and when to remove this message) (Learn how and when to remove this message)

CureVac N.V.

Company type	Public
Traded as	Nasdaq: CVAC
Industry	Biotechnology
Founded	2000; 24 years ago (2000)
Founders	Ingmar Hoerr,[1] Steve Pascolo, Florian von der Muelbe, Günther Jung and Hans-Georg Rammensee
Headquarters	Tübingen, Germany
Key people	Franz-Werner Haas (CEO)
Total equity	€1.40 billion (October 2017)
Number of employees	< 700[2]
Website	www.curevac.com

CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.^[2]

At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus.^[3] Clinical trials for the CureVac COVID-19 Vaccine (CVnCoV) began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company.^[3][4][5] In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy.^[6] In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology.^[7][8]

The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline,^[9][10] Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative,^[11] and the government of Germany.^[12]